Physician

Inderpal Singh, MD

According to 2025 Medicare claims, Inderpal Singh, MD (NPI: 1770572562) practices nephrology in the Florence, SC market, with the plurality of this provider's patient population coming from Florence, SC. This provider's primary affiliated billing organization is PEE DEE NEPHROLOGY LLP (NPI: 1598825929; TIN: 570912581) and primary practice location at 29506-2708. Singh is affiliated with the MUSC Health Alliance, LLC (ACO ID: A5535), participating under the MSSP model.

Singh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 676 traditional Medicare patients, billed 4,982 HCPCS/CPT codes, and received $376,668 in Medicare payments. The top billing code was 99232 (Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes). Part D data shows 6,638 prescription claims across 762 beneficiaries totaling $1,747,812 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 181 claims. Open Payments data shows 1 records totaling $17. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $1,076,926 to $376,668. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,909,655 and ending at $1,747,812. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $16,244 to $2,960.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,682	10,695	$1,076,926
2016	1,434	10,018	$1,110,205
2017	1,327	8,540	$929,734
2018	1,335	9,158	$964,572
2019	1,343	8,936	$1,007,126
2020	1,221	8,090	$944,117
2021	974	5,656	$739,747
2022	827	4,943	$556,869
2023	727	4,365	$420,282
2024	676	4,982	$376,668

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	916	13,913	$1,909,655
2016	924	14,060	$2,598,505
2017	832	12,567	$2,865,323
2018	789	9,962	$1,459,108
2019	774	9,094	$1,749,048
2020	751	7,521	$1,713,764
2021	713	6,741	$1,554,702
2022	710	6,052	$1,381,385
2023	773	6,745	$1,828,981
2024	762	6,638	$1,747,812

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	74	617	$29,292
2016	81	633	$26,446
2017	39	532	$22,530
2018	19	472	$22,936
2019	18	314	$19,585
2020	11	458	$16,540
2021	N/R	406	$50,849
2022	N/R	284	$8,311
2023	N/R	173	$3,732
2024	N/R	181	$3,666

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	229	762	$58
90935	Hemodialysis procedure with physician evaluation	115	266	$52
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	300	659	$52
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	340	805	$12
81002	Urinalysis, manual test	294	632	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	826	31,996	$592,754
Jardiance	Empagliflozin	338	12,913	$253,705
Auryxia	Ferric Citrate	145	4,897	$241,385
Velphoro	Sucroferric Oxyhydroxide	79	2,370	$152,604
Eliquis	Apixaban	88	3,780	$73,250

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7502	Cyclosporine, oral, 100 mg	N	N/R	12	$1,231
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	38	$696
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	51	$614
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	28	$579
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	26	$403

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$17	Travere Therapeutics, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Inderpal Singh, MD?

Tedicare shows public-source Medicare data for Inderpal Singh, MD (NPI 1770572562), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Inderpal Singh, MD have ACO affiliation data?

Inderpal Singh, MD is shown with ACO affiliation data for MUSC Health Alliance, LLC (MSSP, ACO ID A5535).

What billing organization is linked to Inderpal Singh, MD?

Inderpal Singh, MD is linked to PEE DEE NEPHROLOGY LLP (billing NPI 1598825929) in the available physician profile data.

Does Inderpal Singh, MD have Open Payments data?

Inderpal Singh, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.